Role of intracameral bevacizumab in combination with and without Panretinal Photocoagulation (PRP) in neovascular glaucoma patients in our population

Zaheer Ud Din Babar, Tariq Pervaiz Khan

Research output: Contribution to journalArticle

Abstract

Aim: To assess the efficacy of Intracameral (bevacizumab) in combination with and without pan retinal photocoagulation (PRP) in regressing anterior chamber iris and angle neovascularization and stabilizing IOP and improving outcome of secondary neovascular glaucoma in patients with proliferative retinal ischemic disorders in our population. Methods: A Prospective, consecutive, interventional case series study was conducted at AFIO RWP and CMH Khuzdar on a series of patients 25 to 70 years of age. Thirty patients (30 eyes) with NVG secondary to ischemic retinal disorders were enrolled in the study design. The study group included 18(60%) males and 12 (40%) females. Cases were divided into two groups (A, B) and written informed consent was taken prior to procedure. Group A (15 patients) were managed with Intracameral bevacizumab alone While group B (15 patients) received laser pan retinal photocoagulation in addition to Intracameral bevacizumab. Majority had proliferative diabetic retinopathy (21 cases) and remaining nine cases were secondary to ischemic central retinal vein occlusion (CRVO). Baseline records were documented after carrying out complete ophthalmic evaluation in all patients. Follow up was carried out for 03 to 06 months depending on patient compliance. Results: Significantly better reduction of Iris (rubeosis) and anterior chamber angle neovascularization and stabilizing of IOP was observed in Group B who received PRP in addition to Intracameral bevacizumab as compared to group A who were managed with Intracameral bevacizumab alone. Moreover early remission of neovascularization was observed in group A receiving bevacizumab only. Conclusions: Combined procedures seems to be more effective in regressing and stabilizing iris/angle neovascularization, and lowering IOP in patients with NVG particularly in advanced cases.

LanguageEnglish
Pages75-78
Number of pages4
JournalPakistan Journal of Medical and Health Sciences
Volume8
Issue number1
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Fingerprint

Neovascular Glaucoma
Light Coagulation
Population
Iris
Anterior Chamber
Retinal Vein
Retinal Vein Occlusion
Diabetic Retinopathy
Patient Compliance
Bevacizumab
Informed Consent
Lasers

Cite this

@article{cb3529e6faa44e5195d68c1f394a0533,
title = "Role of intracameral bevacizumab in combination with and without Panretinal Photocoagulation (PRP) in neovascular glaucoma patients in our population",
abstract = "Aim: To assess the efficacy of Intracameral (bevacizumab) in combination with and without pan retinal photocoagulation (PRP) in regressing anterior chamber iris and angle neovascularization and stabilizing IOP and improving outcome of secondary neovascular glaucoma in patients with proliferative retinal ischemic disorders in our population. Methods: A Prospective, consecutive, interventional case series study was conducted at AFIO RWP and CMH Khuzdar on a series of patients 25 to 70 years of age. Thirty patients (30 eyes) with NVG secondary to ischemic retinal disorders were enrolled in the study design. The study group included 18(60{\%}) males and 12 (40{\%}) females. Cases were divided into two groups (A, B) and written informed consent was taken prior to procedure. Group A (15 patients) were managed with Intracameral bevacizumab alone While group B (15 patients) received laser pan retinal photocoagulation in addition to Intracameral bevacizumab. Majority had proliferative diabetic retinopathy (21 cases) and remaining nine cases were secondary to ischemic central retinal vein occlusion (CRVO). Baseline records were documented after carrying out complete ophthalmic evaluation in all patients. Follow up was carried out for 03 to 06 months depending on patient compliance. Results: Significantly better reduction of Iris (rubeosis) and anterior chamber angle neovascularization and stabilizing of IOP was observed in Group B who received PRP in addition to Intracameral bevacizumab as compared to group A who were managed with Intracameral bevacizumab alone. Moreover early remission of neovascularization was observed in group A receiving bevacizumab only. Conclusions: Combined procedures seems to be more effective in regressing and stabilizing iris/angle neovascularization, and lowering IOP in patients with NVG particularly in advanced cases.",
keywords = "Anterior chamber angle, Bevacizumab, Iris neovascularization, Neovascularization, Pan retinal photocoagulation",
author = "Babar, {Zaheer Ud Din} and Khan, {Tariq Pervaiz}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "8",
pages = "75--78",
journal = "Pakistan Journal of Medical and Health Sciences",
issn = "1996-7195",
publisher = "Department Of Surgery, Mayo Hospital",
number = "1",

}

TY - JOUR

T1 - Role of intracameral bevacizumab in combination with and without Panretinal Photocoagulation (PRP) in neovascular glaucoma patients in our population

AU - Babar, Zaheer Ud Din

AU - Khan, Tariq Pervaiz

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aim: To assess the efficacy of Intracameral (bevacizumab) in combination with and without pan retinal photocoagulation (PRP) in regressing anterior chamber iris and angle neovascularization and stabilizing IOP and improving outcome of secondary neovascular glaucoma in patients with proliferative retinal ischemic disorders in our population. Methods: A Prospective, consecutive, interventional case series study was conducted at AFIO RWP and CMH Khuzdar on a series of patients 25 to 70 years of age. Thirty patients (30 eyes) with NVG secondary to ischemic retinal disorders were enrolled in the study design. The study group included 18(60%) males and 12 (40%) females. Cases were divided into two groups (A, B) and written informed consent was taken prior to procedure. Group A (15 patients) were managed with Intracameral bevacizumab alone While group B (15 patients) received laser pan retinal photocoagulation in addition to Intracameral bevacizumab. Majority had proliferative diabetic retinopathy (21 cases) and remaining nine cases were secondary to ischemic central retinal vein occlusion (CRVO). Baseline records were documented after carrying out complete ophthalmic evaluation in all patients. Follow up was carried out for 03 to 06 months depending on patient compliance. Results: Significantly better reduction of Iris (rubeosis) and anterior chamber angle neovascularization and stabilizing of IOP was observed in Group B who received PRP in addition to Intracameral bevacizumab as compared to group A who were managed with Intracameral bevacizumab alone. Moreover early remission of neovascularization was observed in group A receiving bevacizumab only. Conclusions: Combined procedures seems to be more effective in regressing and stabilizing iris/angle neovascularization, and lowering IOP in patients with NVG particularly in advanced cases.

AB - Aim: To assess the efficacy of Intracameral (bevacizumab) in combination with and without pan retinal photocoagulation (PRP) in regressing anterior chamber iris and angle neovascularization and stabilizing IOP and improving outcome of secondary neovascular glaucoma in patients with proliferative retinal ischemic disorders in our population. Methods: A Prospective, consecutive, interventional case series study was conducted at AFIO RWP and CMH Khuzdar on a series of patients 25 to 70 years of age. Thirty patients (30 eyes) with NVG secondary to ischemic retinal disorders were enrolled in the study design. The study group included 18(60%) males and 12 (40%) females. Cases were divided into two groups (A, B) and written informed consent was taken prior to procedure. Group A (15 patients) were managed with Intracameral bevacizumab alone While group B (15 patients) received laser pan retinal photocoagulation in addition to Intracameral bevacizumab. Majority had proliferative diabetic retinopathy (21 cases) and remaining nine cases were secondary to ischemic central retinal vein occlusion (CRVO). Baseline records were documented after carrying out complete ophthalmic evaluation in all patients. Follow up was carried out for 03 to 06 months depending on patient compliance. Results: Significantly better reduction of Iris (rubeosis) and anterior chamber angle neovascularization and stabilizing of IOP was observed in Group B who received PRP in addition to Intracameral bevacizumab as compared to group A who were managed with Intracameral bevacizumab alone. Moreover early remission of neovascularization was observed in group A receiving bevacizumab only. Conclusions: Combined procedures seems to be more effective in regressing and stabilizing iris/angle neovascularization, and lowering IOP in patients with NVG particularly in advanced cases.

KW - Anterior chamber angle

KW - Bevacizumab

KW - Iris neovascularization

KW - Neovascularization

KW - Pan retinal photocoagulation

UR - http://www.scopus.com/inward/record.url?scp=84899834700&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 75

EP - 78

JO - Pakistan Journal of Medical and Health Sciences

T2 - Pakistan Journal of Medical and Health Sciences

JF - Pakistan Journal of Medical and Health Sciences

SN - 1996-7195

IS - 1

ER -